Keynote Presentation at Leading European Antibody Conference Highlights Immune Reactivation Mechanisms of Bavituximab

Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial (IST)

Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial

Four AACR Presentations Highlight Broad Therapeutic and Diagnostic Potential of Peregrine's First-in-Class PS-Targeting Platform

Peregrine's PS-Targeting Antibody Significantly Improves Anti-Tumor Effect of Sorafenib in Models of Advanced Liver Cancer

Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EASL

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2011 Financial Results and Recent Developments

Peregrine Pharmaceuticals to Present at Roth Capital Partners OC Growth Stock Conference

Peregrine Appoints Head of Medical Oncology as Company Advances Four Randomized Phase II Trials

Peregrine Announces Initiation of Lung Cancer Investigator-Sponsored Trial